

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> C12N 15/19, C07K 14/52, C12N 15/62, C07K 19/00, 16/24, 16/42, C12Q 1/66, 1/68, G01N 33/52, 33/60	<b>A1</b>	<b>(11) International Publication Number:</b> WO 98/49310 <b>(43) International Publication Date:</b> 5 November 1998 (05.11.98)												
<b>(21) International Application Number:</b> PCT/US98/08212 <b>(22) International Filing Date:</b> 23 April 1998 (23.04.98)  <b>(30) Priority Data:</b> <table border="0" style="width: 100%;"><tr><td style="width: 30%;">60/044,886</td><td style="width: 30%;">25 April 1997 (25.04.97)</td><td style="width: 40%; text-align: right;">US</td></tr><tr><td>08/845,753</td><td>25 April 1997 (25.04.97)</td><td style="text-align: right;">US</td></tr><tr><td>60/071,676</td><td>16 January 1998 (16.01.98)</td><td style="text-align: right;">US</td></tr><tr><td>09/008,543</td><td>16 January 1998 (16.01.98)</td><td style="text-align: right;">US</td></tr></table> <b>(71) Applicant:</b> ZYMOGENETICS, INC. [US/US]; 1201 Eastlake Avenue East, Seattle, WA 98102 (US).  <b>(72) Inventors:</b> PRESNELL, Scott, R.; 919 N. 83rd Street, Seattle, WA 98103 (US). GILBERT, Teresa; 246 12th Street, S.E., Auburn, WA 98002 (US). WHITMORE, Theodore, E.; 6916 152nd Avenue, N.E., Redmond, WA 98052 (US). FOSTER, Donald, C.; 3002 N.E. 181st Street, Seattle, WA 98155 (US). HART, Charles, E.; 20114 183rd Place, N.E., Woodinville, WA 98072 (US). LEHNER, Joyce, M.; 6522 Phinney Avenue North #201, Seattle, WA 98103 (US). MARTINEZ, Theresa; 4591 Honeymoon Bay Road, Greenbank, WA 98253 (US). HOFFMANN, Ross, C.; 503 13th Avenue East #302, Seattle, WA 98102 (US).		60/044,886	25 April 1997 (25.04.97)	US	08/845,753	25 April 1997 (25.04.97)	US	60/071,676	16 January 1998 (16.01.98)	US	09/008,543	16 January 1998 (16.01.98)	US	<b>(74) Agent:</b> LUNN, Paul, G.; ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, WA 98102 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
60/044,886	25 April 1997 (25.04.97)	US												
08/845,753	25 April 1997 (25.04.97)	US												
60/071,676	16 January 1998 (16.01.98)	US												
09/008,543	16 January 1998 (16.01.98)	US												
<b>(54) Title:</b> MAMMALIAN CYTOKINE-LIKE FACTOR 7  <b>(57) Abstract</b>  Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.														

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## MAMMALIAN CYTOKINE-LIKE FACTOR 7

5

BACKGROUND OF THE INVENTION

Proliferation and differentiation of cells of multicellular organisms are controlled by hormones and polypeptide growth factors. These diffusable molecules allow cells to communicate with each other and act in concert to form cells and organs, and to repair and regenerate damaged tissue. Examples of hormones and growth factors include the steroid hormones (e.g. estrogen, testosterone), parathyroid hormone, follicle stimulating hormone, the interleukins, platelet derived growth factor (PDGF), epidermal growth factor (EGF), granulocyte-macrophage colony stimulating factor (GM-CSF), erythropoietin (EPO) and calcitonin.

20

Hormones and growth factors influence cellular metabolism by binding to proteins. Proteins may be integral membrane proteins that are linked to signaling pathways within the cell, such as second messenger systems. Other classes of proteins are soluble molecules, such as the transcription factors.

25

Of particular interest are cytokines, molecules that promote the proliferation and/or differentiation of cells. Examples of cytokines include erythropoietin (EPO), which stimulates the development of red blood cells; thrombopoietin (TPO), which stimulates development of cells of the megakaryocyte lineage; and granulocyte-colony stimulating factor (G-CSF), which stimulates development of neutrophils. These cytokines are useful in restoring normal blood cell levels in patients suffering from anemia or receiving chemotherapy for cancer. The

30

35

demonstrated *in vivo* activities of these cytokines illustrates the enormous clinical potential of, and need for, other cytokines, cytokine agonists, and cytokine antagonists.

5

#### SUMMARY OF THE INVENTION

The present invention addresses this need by providing a novel polypeptide called cytokine-like factor 7, hereinafter referred to as Zcyto7 and related compositions and methods.

Thus, one aspect of the present invention provides for an isolated Zcyto7 polypeptide having amino acid sequences as follows. Both the human and the mouse cDNAs have been discovered. The human sequences are defined by SEQ ID NOs: 1 and 2. The murine nucleotide and amino acid sequences are defined by SEQ ID NOs: 11 and 12.

The nucleotide sequence of SEQ ID NO:1 contains an open reading frame encoding a polypeptide of about 180 amino acids with the initial Met as shown in SEQ ID NO:1 and SEQ ID NO:2. A predicted signal sequence is comprised of amino acid residues 1-20, and the resultant predicted mature Zcyto7 polypeptide is represented by the amino acid sequence extending from amino acid residue 21, a glutamine to and including amino acid residue 180 a phenylalanine, also represented by SEQ ID NO: 14. Peptide mapping data indicate that mature Zcyto7 can be comprised of a number of N-terminal mature variants including the amino acid sequence extending from amino acid residue 23, an arginine to and including amino acid residue 180 of SEQ ID NO: 2, also defined by SEQ ID NO: 36; amino acid sequence extending from amino acid residue 27, a serine to and including amino acid residue 180 of SEQ ID NO: 2, also defined by SEQ ID NO: 37; the amino acid sequence defined

by amino acid residue 30, a lysine, to and including amino acid residue 180 of SEQ ID NO: 2, also defined by SEQ ID NO: 38; amino acid sequence extending from amino acid 28, a lysine, to and including amino acid residue 180 of SEQ ID NO: 2, also defined by SEQ ID NO: 41 and the amino acid sequence extending from amino acid residue 53, a methionine, to and including amino acid residue 180, also defined by SEQ ID NO: 42. The only observed cleavage at the carboxyl terminus is the phenylalanine at position 180 can be cleaved off. This can occur in all of the above-defined mature Zcyto7 polypeptides an example of which is shown by SEQ ID NO: 43. Additional variants of human Zcyto7 are defined by SEQ ID NOs: 15-25. Within an additional embodiment, the polypeptide further comprises an affinity tag.

SEQ ID NOs: 11 and 12 define murine Zcyto7 wherein the mature protein extends from amino acid residues amino acid residue 21, a histidine, to and including amino acid residue 180 a phenylalanine, also defined by SEQ ID NO: 39; or as an alternative splice site from amino acid residue 23, an arginine, to and including amino acid 180 also defined by SEQ ID NO: 40. The present invention is also comprised of polypeptides having an amino acid sequence at least 90% identical, more preferably 95%, 97% or 99% identical to those Zcyto7 polypeptides defined in above.

An additional embodiment of the present invention relates to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a Zcyto7 polypeptide having an amino acid sequence described above. Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a Zcyto7 polypeptide of the present invention include portions of

such polypeptides with at least nine, preferably at least 15 and more preferably at least 30 to 50 amino acids, although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a

5 polypeptide of the present invention described above are also included in the present invention. Examples of said polypeptides are defined by the amino acid sequences of SEQ ID NOS: 25-35. Also claimed are any of these polypeptides that are fused to another polypeptide or

10 carrier molecule.

The present invention further comprises a polypeptide defined by SEQ ID NOS: 15-25 wherein the amino termini of said polypeptides are modified and begin at

15 either amino acid residue 3, an arginine; amino acid residue 7, a serine; amino acid residue 8, a lysine; amino acid residue 10, a lysine or amino acid residue 33 methionine.

20 The present invention is further comprised of a polypeptide wherein the polypeptide is a polypeptide defined by SEQ ID NOS: 2, 12, 14-25 and 36 to 42 wherein the amino acid sequences end at the isoleucines at amino acid residue 179 of SEQ ID NO: 2, at amino acid residue

25 159 of SEQ ID NOS: 14-25, which corresponds to amino acid residue 157 of SEQ ID NO:36, amino acid residue 153 of SEQ ID NO:37, amino acid residue 150 of SEQ ID NO:38, amino acid residue 159 of SEQ ID NO: 39, amino acid residue 157 of SEQ ID NO:40, amino acid residue 152 SEQ ID NO:42,

30 amino acid residue 127 of SEQ ID NO:42.

The present invention is further comprised of an isolated peptide or polypeptide of the above-described peptides or polypeptide having an amino acid sequence

35 modified by addition, deletion and/or replacement of one

or more amino acid residues and which maintains the biological activity of said peptide or polypeptide.

5           Within a further aspect of the invention there is provided a chimeric polypeptide consisting essentially of a first portion and a second portion joined by a peptide bond. The first portion of the chimeric polypeptide consists essentially of (a) a Zcyto7  
10 polypeptide as described above (b) allelic variants of the polypeptides described above. The second portion of the chimeric polypeptide consists essentially of another polypeptide such as an affinity tag. Within one  
15 embodiment the affinity tag is an immunoglobulin F<sub>C</sub> polypeptide. The invention also provides expression vectors encoding the chimeric polypeptides and host cells transfected to produce the chimeric polypeptides.

          Another aspect of the present invention provides  
20 for isolated nucleic acid molecules comprising a polynucleotide selected from the group consisting of: (a) a nucleotide sequence encoding the Zcyto7 polypeptides described above; (b) a nucleotide sequence encoding the polypeptides of SEQ ID NOS: 14-40 and (c) a nucleotide  
25 sequence complementary to any of to any of the nucleotide sequences in (a) or (b).

          Further embodiments of the invention include isolated nucleic acid molecules that comprise a  
30 polynucleotide having a nucleotide sequence at least 90% identical, and more preferably 95%, 97%, 98%, or 99% identical to any of the nucleotide sequences in (a), (b) or (c) above, or a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide  
35 having a nucleotide sequence of (a) (b) or (c) above. An additional nucleic acid embodiment of the present

invention relates to an isolated nucleic acid molecule comprising an amino acid of an epitope-bearing portion of a Zcyto7 polypeptide.

5           Within another aspect of the invention there is provided an expression vector comprising (a) a transcription promoter; (b) a DNA segment encoding a polypeptide described above, and (c) a transcription terminator, wherein the promoter, DNA segment, and  
10 terminator are operably linked.

          Within a third aspect of the invention there is provided a cultured eukaryotic cell into which has been introduced an expression vector as disclosed above,  
15 wherein said cell expresses a protein polypeptide encoded by the DNA segment.

          In another embodiment of the present invention is an isolated antibody that binds specifically to a  
20 Zcyto7 polypeptide described above. Also claimed is a method for producing antibodies which bind to a Zcyto7 polypeptide comprising inoculating a mammal with a Zcyto7 polypeptide or Zcyto7 epitope-bearing polypeptide so that the mammal produces antibodies to the polypeptide; and  
25 isolating said antibodies.

          These and other aspects of the invention will become evident upon reference to the following detailed description.

30

#### DETAILED DESCRIPTION OF THE INVENTION

          The teachings of all of the references cited herein are incorporated in their entirety herein by  
35 reference.



The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a poly-histidine tract, protein A [Nilsson et al, *EMBO J.* 4:1075 (1985); Nilsson et al., *Methods Enzymol.* 198:3 (1991)], glutathione S transferase [Smith and Johnson, *Gene* 67:31 (1988)], Glu-Glu affinity tag [Grussenmeyer et al., *Proc. Natl. Acad. Sci. USA* 82:7952-4 (1985)], substance P, FLAG<sup>TM</sup> peptide (Hopp et al., *Biotechnology* 6:1204-10 (1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., *Protein Expression and Purification* 2: 95-107 (1991). DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

20

The term "allelic variant" denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

30

The term "expression vector" denotes a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments may include promoter and

35

terminator sequences, and may optionally include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from  
5 plasmid or viral DNA, or may contain elements of both.

The term "isolated", when applied to a polynucleotide molecule, denotes that the polynucleotide has been removed from its natural genetic milieu and is  
10 thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones.  
15 Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to  
20 one of ordinary skill in the art. See for example, Dynan and Tijan, *Nature* 316:774-78 (1985). When applied to a protein, the term "isolated" indicates that the protein is found in a condition other than its native environment, such as apart from blood and animal tissue. In a  
25 preferred form, the isolated protein is substantially free of other proteins, particularly other proteins of animal origin. It is preferred to provide the protein in a highly purified form, i.e., greater than 95% pure, more preferably greater than 99% pure.

30

The term "operably linked", when referring to DNA segments, denotes that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in the promoter and proceeds  
35 through the coding segment to the terminator

The term "polynucleotide" denotes a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated  
5 from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules.

The term "complements of polynucleotide molecules" denotes polynucleotide molecules having a  
10 complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

15 The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of  
20 nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

The term "promoter" denotes a portion of a gene containing DNA sequences that provide for the binding of  
25 RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

The term "secretory signal sequence" denotes a  
30 DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger peptide is commonly cleaved to remove the secretory peptide during  
35 transit through the secretory pathway.

The term "receptor" denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell. Membrane-bound receptors are characterized by a multi-domain structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. Most nuclear receptors also exhibit a multi-domain structure, including an amino-terminal, transactivating domain, a DNA binding domain and a ligand binding domain. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).

The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the

complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of  $<10^9 \text{ M}^{-1}$ .

- 5           A "soluble protein" is a protein polypeptide that is not bound to a cell membrane.

Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar  
10 sized regions of the DNA of SEQ ID NO:1, or a sequence complementary thereto, under stringent conditions. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is  
15 the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typical stringent conditions are those in which the salt concentration is about 0.02 M or less at pH 7 and the temperature is at least about 60°C. As  
20 previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for isolating DNA and RNA are well known in the art. Total RNA can be prepared using guanidine HCl extraction followed by isolation by centrifugation in a CsCl gradient [Chirgwin  
25 et al., *Biochemistry* 18:52-94 (1979)]. Poly (A)<sup>+</sup> RNA is prepared from total RNA using the method of Aviv and Leder, *Proc. Natl. Acad. Sci. USA* 69:1408-1412 (1972). Complementary DNA (cDNA) is prepared from poly(A)<sup>+</sup> RNA using known methods. Polynucleotides encoding Zcyto7  
30 polypeptides are then identified and isolated by, for example, hybridization or PCR.

Additionally, the polynucleotides of the present invention can be synthesized using a DNA synthesizer.  
35 Currently the method of choice is the phosphoramidite method. If chemically synthesized double stranded DNA is

required for an application such as the synthesis of a gene or a gene fragment, then each complementary strand is made separately. The production of short genes (60 to 80 bp) is technically straightforward and can be accomplished by synthesizing the complementary strands and then annealing them. For the production of longer genes (>300 bp), however, special strategies must be invoked, because the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are assembled in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length. In addition to the protein coding sequence, synthetic genes can be designed with terminal sequences that facilitate insertion into a restriction endonuclease sites of a cloning vector and other sequences should also be added that contain signals for the proper initiation and termination of transcription and translation.

See Glick, Bernard R. and Jack J. Pasternak, *Molecular Biotechnology, Principles & Applications of Recombinant DNA*, (ASM Press, Washington, D.C. 1994), Itakura, K. et al. Synthesis and use of synthetic oligonucleotides. *Annu. Rev. Biochem.* 53 : 323-356 (1984), and Climie, S. et al. Chemical synthesis of the thymidylate synthase gene. *Proc. Natl. Acad. Sci. USA* 87 :633-637 (1990).

Those skilled in the art will recognize that the sequences disclosed in SEQ ID NOS:1 and 2 represent a single allele of the human. There are a number of naturally occurring mature N-terminal variants having the leader sequence cleaved at differing positions. They include the sequences defined by SEQ ID NOs 14, 36, 37 and 38. Allelic variants of these sequences can be cloned by probing cDNA or genomic libraries from different

individuals according to standard procedures. Examples of variants of human Zcyto7 are represented by the polypeptides of SEQ ID NOs: 15-25.

5           The murine Zcyto7 cDNA and protein are disclosed by SEQ ID NOs: 11 and 12. The mature Zcyto7 polypeptide is defined by SEQ ID NOs: 39 and 40.

          The present invention further provides  
10 counterpart proteins and polynucleotides from other species ("species orthologs"). Of particular interest are Zcyto7 polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primates. Species orthologs of the  
15 human Zcyto7 protein can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the protein. Suitable  
20 sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A protein-encoding cDNA can then be isolated by a variety of methods, such as by  
25 probing with a complete or partial human or mouse cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned using the polymerase chain reaction, or PCR (Mullis, U.S. Patent No. 4,683,202), using primers designed from the sequences  
30 disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to the protein. Similar techniques can also be applied to the isolation of genomic clones. As  
35 used and claimed the language "an isolated polynucleotide which encodes a polypeptide, said polynucleotide being

defined by SEQ ID NO: 2" includes all allelic variants and species orthologs of the polypeptide of SEQ ID NO:2.

The present invention also provides isolated  
 5 protein polypeptides that are substantially homologous to  
 the protein polypeptides of SEQ ID NO: 2 and its species  
 orthologs. By "isolated" is meant a protein or  
 polypeptide that is found in a condition other than its  
 native environment, such as apart from blood and animal  
 10 tissue. In a preferred form, the isolated polypeptide is  
 substantially free of other polypeptides, particularly  
 other polypeptides of animal origin. It is preferred to  
 provide the polypeptides in a highly purified form, i.e.  
 greater than 95% pure, more preferably greater than 99%  
 15 pure. The term "substantially homologous" is used herein  
 to denote polypeptides having 50%, preferably 60%, more  
 preferably at least 80%, sequence identity to the sequence  
 shown in SEQ ID NO:2, or its species orthologs. Such  
 polypeptides will more preferably be at least 90%  
 20 identical, and most preferably 95% or more identical to  
 SEQ ID NO:2, or its species orthologs. Percent sequence  
 identity is determined by conventional methods. See, for  
 example, Altschul et al., *Bull. Math. Bio.* 48: 603-616  
 (1986) and Henikoff and Henikoff, *Proc. Natl. Acad. Sci.*  
 25 *USA* 89:10915-10919 (1992). Briefly, two amino acid  
 sequences are aligned to optimize the alignment scores  
 using a gap opening penalty of 10, a gap extension penalty  
 of 1, and the "blossom 62" scoring matrix of Henikoff and  
 Henikoff (ibid.) as shown in Table 2 (amino acids are  
 30 indicated by the standard one-letter codes). The percent  
 identity is then calculated as:

$$\frac{\text{Total number of identical matches}}{\text{[length of the longer sequence plus the}} \times 100$$

35 number of gaps introduced into the longer  
 sequence in order to align the two  
 sequences]





Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed above.

5                   Substantially homologous proteins and polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 3) and other  
10 substitutions that do not significantly affect the folding or activity of the protein or polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about  
15 20-25 residues, or a small extension that facilitates purification (an affinity tag), such as a poly-histidine tract, protein A [Nilsson et al., *EMBO J.* 4:1075 (1985); Nilsson et al., *Methods Enzymol.* 198:3, (1991)], glutathione S transferase [Smith and Johnson, *Gene* 67:31, (1988)], or other antigenic epitope or binding domain.  
20 See, in general Ford et al., *Protein Expression and Purification* 2: 95-107 (1991). DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

25

Table 3Conservative amino acid substitutions

30	Basic:	arginine
		lysine
		histidine
	Acidic:	glutamic acid
		aspartic acid
	Polar:	glutamine
		asparagine
35	Hydrophobic:	leucine
		isoleucine

Table 3, continued

		valine
	Aromatic:	phenylalanine
		tryptophan
5		tyrosine
	Small:	glycine
		alanine
		serine
		threonine
10		methionine

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis [Cunningham and Wells, *Science* 244: 1081-1085 (1989); Bass et al., *Proc. Natl. Acad. Sci. USA* 88:4498-4502 (1991)]. In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (e.g., ligand binding and signal transduction) to identify amino acid residues that are critical to the activity of the molecule. Sites of ligand-protein interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al., *Science* 255:306-312 (1992); Smith et al., *J. Mol. Biol.* 224:899-904, 1992; Wlodaver et al., *FEBS Lett.* 309:59-64 (1992). The identities of essential amino acids can also be inferred from analysis of homologies with related proteins.

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer, *Science* 241:53-57 (1988) or Bowie and Sauer, *Proc. Natl.*

Acad. Sci. USA 86:2152-2156 (1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display, e.g., Lowman et al., *Biochem.* 30:10832-10837 (1991); Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204) and region-directed mutagenesis, Derbyshire et al., *Gene* 46:145 (1986); Ner et al., *DNA* 7:127 (1988).

Mutagenesis methods as disclosed above can be combined with high-throughput screening methods to detect activity of cloned, mutagenized proteins in host cells. Preferred assays in this regard include cell proliferation assays and biosensor-based ligand-binding assays, which are described below. Mutagenized DNA molecules that encode active proteins or portions thereof (e.g., ligand-binding fragments) can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

Using the methods discussed above, one of ordinary skill in the art can prepare a variety of polypeptides that are substantially homologous to SEQ ID NO:2 or allelic variants thereof and retain the properties of the wild-type protein. As expressed and claimed herein the language, "a polypeptide as defined by SEQ ID NO: 2" includes all allelic variants and species orthologs of the polypeptide.

Another embodiment of the present invention provides for a peptide or polypeptide comprising an

epitope-bearing portion of a polypeptide of the invention. The epitope of the this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention. A region of a protein to which an antibody can  
5 bind is defined as an "antigenic epitope". See for instance, Geysen, H.M. et al., *Proc. Natl. Acad Sci. USA* 81:3998-4002 (1984).

As to the selection of peptides or polypeptides  
10 bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in the art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts  
15 with the partially mimicked protein. See Sutcliffe, J.G. et al. *Science* 219:660-666 (1983). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither  
20 to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein;  
25 longer soluble peptides, especially those containing proline residues, usually are effective.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise  
30 antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. Antigenic epitope-bearing peptides and polypeptides of the present invention contain a sequence of at least nine, preferably between 15 to about 30 amino acids contained within the  
35 amino acid sequence of a polypeptide of the invention. However, peptides or polypeptides comprising a larger

portion of an amino acid sequence of the invention, containing from 30 to 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are useful for inducing  
5 antibodies that react with the protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (*i.e.*, the sequence includes relatively hydrophilic residues and hydrophobic residues are  
10 preferably avoided); and sequences containing proline residues are particularly preferred. All of the polypeptides shown in the sequence listing contain antigenic epitopes to be used according to the present invention, however, specifically designed antigenic  
15 epitopes include the peptides defined by SEQ ID NOs: 27-35.

Polynucleotides, generally a cDNA sequence, of the present invention encode the above-described polypeptides. A cDNA sequence which encodes a polypeptide  
20 of the present invention is comprised of a series of codons, each amino acid residue of the polypeptide being encoded by a codon and each codon being comprised of three nucleotides. The amino acid residues are encoded by their respective codons as follows.

25

Alanine (Ala) is encoded by GCA, GCC, GCG or GCT;

Cysteine (Cys) is encoded by TGC or TGT;

Aspartic acid (Asp) is encoded by GAC or GAT;

Glutamic acid (Glu) is encoded by GAA or GAG;

30

Phenylalanine (Phe) is encoded by TTC or TTT;

Glycine (Gly) is encoded by GGA, GGC, GGG or GGT;

Histidine (His) is encoded by CAC or CAT;

Isoleucine (Ile) is encoded by ATA, ATC or ATT;

Lysine (Lys) is encoded by AAA, or AAG;

35

Leucine (Leu) is encoded by TTA, TTG, CTA, CTC,

CTG or CTT;

Methionine (Met) is encoded by ATG;  
Asparagine (Asn) is encoded by AAC or AAT;  
Proline (Pro) is encoded by CCA, CCC, CCG or CCT;  
Glutamine (Gln) is encoded by CAA or CAG;  
5 Arginine (Arg) is encoded by AGA, AGG, CGA, CGC,  
CGG or CGT;  
Serine (Ser) is encoded by AGC, AGT, TCA, TCC,  
TCG or TCT;  
Threonine (Thr) is encoded by ACA, ACC, ACG or  
10 ACT;  
Valine (Val) is encoded by GTA, GTC, GTG or GTT;  
Tryptophan (Trp) is encoded by TGG; and  
Tyrosine (Tyr) is encoded by TAC or TAT.

15 It is to be recognized that according to the  
present invention, when a cDNA is claimed as described  
above, it is understood that what is claimed are both the  
sense strand, the anti-sense strand, and the DNA as double-  
stranded having both the sense and anti-sense strand  
20 annealed together by their respective hydrogen bonds. Also  
claimed is the messenger RNA (mRNA) which encodes the  
polypeptides of the present invention, and which mRNA is  
encoded by the above-described cDNA. A messenger RNA (mRNA)  
will encode a polypeptide using the same codons as those  
25 defined above, with the exception that each thymine  
nucleotide (T) is replaced by a uracil nucleotide (U).

The protein polypeptides of the present  
invention, including full-length proteins, protein  
30 fragments (e.g. receptor-binding fragments), and fusion  
polypeptides can be produced in genetically engineered host  
cells according to conventional techniques. Suitable host  
cells are those cell types that can be transformed or  
transfected with exogenous DNA and grown in culture, and  
35 include bacteria, fungal cells, and cultured higher  
eukaryotic cells. Eukaryotic cells, particularly cultured

cells of multicellular organisms, are preferred.

Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al., *Molecular Cloning: A*

- 5 *Laboratory Manual*, (2nd ed.) (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and Ausubel et al., *ibid.*

- 10 In general, a DNA sequence encoding a Zcyto7 polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication,
- 15 although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers,
- 20 vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

- 25 To direct a Zcyto7 polypeptide into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of the protein, or
- 30 may be derived from another secreted protein (e.g., t-PA) or synthesized *de novo*. The secretory signal sequence is joined to the Zcyto7 DNA sequence in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of
- 35 interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see,



e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

Cultured mammalian cells are preferred hosts  
5 within the present invention. Methods for introducing  
exogenous DNA into mammalian host cells include calcium  
phosphate-mediated transfection, Wigler et al., *Cell* 14:725  
(1978); Corsaro and Pearson, *Somatic Cell Genetics* 7:603  
(1981); Graham and Van der Eb, *Virology* 52:456 (1973),  
10 electroporation, Neumann et al., *EMBO J.* 1:841-845 (1982),  
DEAE-dextran mediated transfection, Ausubel et al., eds.,  
*Current Protocols in Molecular Biology* (John Wiley and  
Sons, Inc., NY, 1987), and liposome-mediated transfection  
(Hawley-Nelson et al., *Focus* 15:73 (1993); Ciccarone et  
15 al., *Focus* 15:80 (1993). The production of recombinant  
polypeptides in cultured mammalian cells is disclosed, for  
example, by Levinson et al., U.S. Patent No. 4,713,339;  
Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al.,  
U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No.  
20 4,656,134. Suitable cultured mammalian cells include the  
COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK  
(ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293  
[ATCC No. CRL 1573; Graham et al., *J. Gen. Virol.* 36:59-72  
(1977)] and Chinese hamster ovary (e.g. CHO-K1; ATCC No.  
25 CCL 61) cell lines. Additional suitable cell lines are  
known in the art and available from public depositories  
such as the American Type Culture Collection, Rockville,  
Maryland. In general, strong transcription promoters are  
preferred, such as promoters from SV-40 or cytomegalovirus.  
30 See, e.g., U.S. Patent No. 4,956,288. Other suitable  
promoters include those from metallothionein genes (U.S.  
Patent Nos. 4,579,821 and 4,601,978) and the adenovirus  
major late promoter.

35 Drug selection is generally used to select for  
cultured mammalian cells into which foreign DNA has been

inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems may also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g. hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used.

Other higher eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al., U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., *J. Biosci. (Bangalore)* 11:47-58 (1987).

Fungal cells, including yeast cells, and particularly cells of the genus *Saccharomyces*, can also be used within the present invention, such as for producing protein fragments or polypeptide fusions. Methods for transforming yeast cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for

example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed  
5 cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in yeast is the *POT1* vector system disclosed by Kawasaki et al., U.S.  
10 Patent No. 4,931,373, which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No.  
15 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*,  
20 *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., *J. Gen. Microbiol.* 132:3459-3465 (1986) and Cregg, U.S. Patent No. 4,882,279.  
25 *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S.  
30 Patent No. 4,486,533.

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required  
35 for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media,

are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will  
5 generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell.

10

Within one aspect of the present invention, a novel protein is produced by a cultured cell, and the cell is used to screen for a receptor or receptors for the protein, including the natural receptor, as well as  
15 agonists and antagonists of the natural ligand.

#### PROTEIN ISOLATION:

Expressed recombinant polypeptides (or chimeric  
20 polypeptides) can be purified using fractionation and/or conventional purification methods and media. Ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size  
25 exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable anion exchange media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred, with DEAE Fast-Flow Sepharose  
30 (Pharmacia, Piscataway, NJ) being particularly preferred. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and  
35 the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include

glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties. Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Methods for binding receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine design and is determined in part by the properties of the chosen support. See, for example, *Affinity Chromatography: Principles & Methods* (Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988).

The polypeptides of the present invention can be isolated by exploitation of their properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich proteins. Briefly, a gel is first charged with divalent metal ions to form a chelate [E. Sulkowski, *Trends in Biochem.* 3:1-7 (1985)].

Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography [*Methods in Enzymol.*, Vol. 182:529-39, "Guide to Protein Purification", M. Deutscher, (ed.), (Acad. Press, San Diego, 1990)]. Alternatively, a fusion of

the polypeptide of interest and an affinity tag (e.g., polyhistidine, maltose-binding protein, an immunoglobulin domain) may be constructed to facilitate purification. Furthermore, to facilitate purification of the secreted  
5 receptor polypeptide, an amino or carboxyl-terminal extension, such as a poly-histidine tag, substance P, FLAG® peptide [Hopp et al., *Bio/Technology* 6:1204-1210 (1988); available from Eastman Kodak Co., New Haven, CT), a Glu-Glu affinity tag [Grussenmeyer et al., *Proc. Natl. Acad. Sci.*  
10 *USA* 82:7952-4 (1985)], or another polypeptide or protein for which an antibody or other specific binding agent is available, can be fused to Zcyto7 to aid in purification.

#### Uses

15

Northern blot analysis of the expression of Zcyto7 reveals that Zcyto7 is specifically expressed in the spinal cord. *In situ* analysis of the spinal cord reveals that this expression is localized in the neurons and dorsal  
20 root ganglia. Therefore, Zcyto7 may play a role in the maintenance of spinal cord involving either glial cells or neurons. This indicates that Zcyto7 can be used to treat a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), or demyelinating diseases  
25 including multiple sclerosis. Zcyto7 may also be used to treat sensory neuropathies. The tissue specificity of Zcyto7 expression suggests that Zcyto7 may be a growth and/or maintenance factor in the spinal cord.

30

Zcyto7 gene's location on chromosome 5 indicates that zcyto7 is a cytokine which can be used to modulate the activities of cells of the immune system. Zcyto7 can also be used as a chemoattractant of neutrophils in the spinal column. This would be useful as an anti-infective for  
35 infections in the spinal column. It could also be used to help regulate other cytokines in the spinal cord. Zcyto7

may also be administered to treat peripheral neuropathies such as Charcot-Marie-Tooth (CMT) disease which is localized to the same chromosomal region of 5q as Zcyto7.

5           The fact that Zcyto7 inhibits the growth of BAF-3 and TF-1 cells as shown in examples 11 and 12 below indicates that Zcyto7 can be used to treat autoimmune diseases and possibly such cancers such as leukemias.

10           The present invention also provides reagents which will find use in diagnostic applications. For example, the Zcyto7 gene is heavily expressed in the spinal cord. A probe comprising the Zcyto7 DNA or RNA or a subsequence thereof can be used to determine if the Zcyto7  
15 gene is present on chromosome 5 or if a mutation has occurred.

          The present invention also provides reagents with significant therapeutic value. The Zcyto7 polypeptide  
20 (naturally occurring or recombinant), fragments thereof, antibodies and anti-idiotypic antibodies thereto, along with compounds identified as having binding affinity to the Zcyto7 polypeptide, should be useful in the treatment of conditions associated with abnormal physiology or  
25 development, including abnormal proliferation, e.g., cancerous conditions, or degenerative conditions. For example, a disease or disorder associated with abnormal expression or abnormal signaling by a Zcyto7 polypeptide should be a likely target for an agonist or antagonist of  
30 the Zcyto7 polypeptide.

          In particular, Zcyto7 can be used to treat inflammation. Inflammation is a result of an immune response to an infection or as an autoimmune response to a  
35 self-antigen.

Treatment dosages should be titrated to optimize safety and efficacy. Methods for administration include intravenous, peritoneal, intramuscular, subdural, into the spinal fluid or transdermal administration.

- 5 Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from 0.1 $\mu$ g to 1mg per kilogram of body weight per day. Preferably, 1 $\mu$ g to 100 $\mu$ g per day. However, the doses may be higher or lower as can be
- 10 determined by a medical doctor with ordinary skill in the art. For a complete discussion of drug formulations and dosage ranges see *Remington's Pharmaceutical Sciences*, 17<sup>th</sup> Ed., (Mack Publishing Co., Easton, Penn., 1990), and *Goodman and Gilman's: The Pharmacological Bases of*
- 15 *Therapeutics*, 9<sup>th</sup> Ed. (Pergamon Press 1996).

#### Use of Zcyto7 to Promote Bone and Cartilage Growth

- 20 It has been discovered that Zcyto7 stimulates the proliferation of both chondrocytes and osteoblasts as is shown below in Examples 7 and 9 respectively. In addition, Zcyto7 also stimulates the steady state level of glycosaminoglycan present in chondrocyte cultures as shown
- 25 in Example 8. Thus Zcyto7 can be used to stimulate both bone and cartilage growth in a variety of different therapeutic settings.

- 30 Zcyto7 can be implanted in a mammalian body so that the zcyto7 is in contact with osteoblasts such that osteoblast proliferation occurs and bone growth is stimulated. For example, zcyto7 can be placed in a matrix [with or without a bone morphogenic protein (BMP)]. The BMP induces the migration of mesenchymal osteoblast precursors
- 35 to the site and further induces differentiation of the mesenchymal cells into osteoblast. Zcyto7 will then



stimulate the further proliferation of the osteoblasts. A suitable matrix is made up of particles of porous materials. The pores must be of a dimension to permit progenitor cell migration and subsequent differentiation and proliferation. An ideal particle size should be in the range of 70 - 850  $\mu\text{m}$ , preferably 150 - 420 $\mu\text{m}$ . The matrix containing the zcyto7 can be molded into a shape encompassing a bone defect. Examples of matrix materials are particulate, demineralized, guanidine extracted, species-specific bone. Other potentially useful matrix materials include collagen, homopolymers and copolymers of glycolic acid and lactic acid, hydroxyapatite, tricalcium phosphate and other calcium phosphates. Zcyto7 can be applied into a matrix at a sufficient concentration to promote the proliferation of osteoblasts, preferably at a concentration of at least  $1\mu\text{g}/\text{ml}$  of matrix. A solution of zcyto7 can also be injected directly into the site of a bone fracture or defect including areas of bone degeneration to expedite healing of the fracture or defect site. Examples of BMPs and the use of matrices to produce are disclosed in PCT application publication number WO 92/07073, publication No. WO 91/05802, U.S Patent No. 5,645,591 and U.S. Patent No. 5,108,753.

Zcyto7 can be further used to treat osteoporosis by administering a therapeutically effective amount of zcyto7 to an individual. A preferred dosage would be  $1\mu\text{g}$  of zcyto7 per kilogram of body weight per day.

As stated above, it has also been determined that zcyto7 can be used to promote the production of cartilage through its ability to stimulate the proliferation of chondrocytes. Zcyto7 can be injected directly into the site where cartilage is to be grown. For example, zcyto7 can be injected directly in joints which have been afflicted with osteoarthritis or other injured joints in which the

cartilage has been worn down. An example of a case in which additional cartilage needs to be grown is shoulders and knees of injured athletes.

5           Cartilage can also be grown by first removing chondrocytes from an individual, culturing the chondrocytes with zcyto7 so that they proliferate and reimplanting the chondrocytes back into the individual where cartilage needs to be produced.

10

          Zcyto7 can also be used to stimulate the regeneration of dentin or bone which has been lost due to periodontal disease. To do this, the surrounding tissue should be thoroughly cleaned and a solution of Zcto7 be  
15 administered, preferably by injection, into the site in which dentin regeneration is desired.

          Antibodies to the zcyto7 polypeptide can be purified and then administered to a patient. These reagents  
20 can be combined for therapeutic use with additional active or inert ingredients, e.g., in pharmaceutically acceptable carriers or diluents along with physiologically innocuous stabilizers and excipients. These combinations can be sterile filtered and placed into dosage forms as by  
25 lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies, binding fragments thereof or single-chain antibodies of the antibodies including forms which are not complement binding.

30

          The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medications  
35 administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in

vitro may provide useful guidance in the amounts useful for in vivo administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage.

- 5 Methods for administration include oral, intravenous, peritoneal, intramuscular, or transdermal administration. Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from 1µg to 1000µg per kilogram of  
10 body weight per day. However, the doses may be higher or lower as can be determined by a medical doctor with ordinary skill in the art. For a complete discussion of drug formulations and dosage ranges see *Remington's Pharmaceutical Sciences*, 17<sup>th</sup> Ed., (Mack Publishing Co.,  
15 Easton, Penn., 1990), and *Goodman and Gilman's: The Pharmacological Bases of Therapeutics*, 9<sup>th</sup> Ed. (Pergamon Press 1996).

#### Nucleic Acid-based Therapeutic Treatment

20

- If a mammal has a mutated or lacks a *Zcyto7* gene, the *Zcyto7* gene can be introduced into the cells of the mammal. In one embodiment, a gene encoding a *Zcyto7* polypeptide is introduced in vivo in a viral vector. Such  
25 vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral  
30 genes, are preferred. A defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Examples of particular vectors include, but  
35 are not limited to, a defective herpes virus 1 (HSV1) vector [Kaplitt et al., *Molec. Cell. Neurosci.*, 2 :320-330

(1991)], an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet *et al.*, *J. Clin. Invest.*, 90 :626-630 (1992), and a defective adeno-associated virus vector [Samulski *et al.*, *J. Virol.*, 5 61:3096-3101 (1987); Samulski *et al.* *J. Virol.*, 63:3822-3828 (1989)].

In another embodiment, the gene can be introduced in a retroviral vector, e.g., as described in Anderson *et al.*, U.S. Patent No. 5,399,346; Mann *et al.*, *Cell*, 33:153 10 (1983); Temin *et al.*, U.S. Patent No. 4,650,764; Temin *et al.*, U.S. Patent No. 4,980,289; Markowitz *et al.*, *J. Virol.*, 62:1120 (1988); Temin *et al.*, U.S. Patent No. 5,124,263; International Patent Publication No. WO 15 95/07358, published March 16, 1995 by Dougherty *et al.*; and *Blood*, 82:845 (1993).

Alternatively, the vector can be introduced by lipofection *in vivo* using liposomes. Synthetic cationic 20 lipids can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker [Felgner *et al.*, *Proc. Natl. Acad. Sci. USA*, 84:7413-7417 (1987); see Mackey *et al.*, *Proc. Natl. Acad. Sci. USA*, 85:8027-8031 (1988)]. The use of lipofection to introduce exogenous genes into 25 specific organs *in vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cells represents one area of benefit. It is clear that directing transfection to 30 particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain. Lipids may be chemically coupled to other molecules for the purpose of targeting. Targeted peptides, e.g., hormones or neurotransmitters, and proteins 35 such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

It is possible to remove the cells from the body and introduce the vector as a naked DNA plasmid and then re-implant the transformed cells into the body. Naked DNA  
5 vector for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter [see, e.g., Wu  
10 et al., *J. Biol. Chem.*, 267:963-967 (1992); Wu et al., *J. Biol. Chem.*, 263:14621-14624 (1988)].

Zcyto7 polypeptides can also be used to prepare antibodies that specifically bind to Zcyto7 polypeptides.  
15 These antibodies can then be used to manufacture anti-idiotypic antibodies. As used herein, the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, antigen-binding fragments thereof such as  $F(ab')_2$  and Fab fragments, and the like, including genetically engineered  
20 antibodies. Antibodies are defined to be specifically binding if they bind to a Zcyto7 polypeptide with a  $K_a$  of greater than or equal to  $10^7/M$ . The affinity of a monoclonal antibody can be readily determined by one of ordinary skill in the art (see, for example, Scatchard,  
25 *ibid.*).

Methods for preparing polyclonal and monoclonal antibodies are well known in the art (see for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*,  
30 (Second Edition) (Cold Spring Harbor, NY, 1989); and Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications* (CRC Press, Inc., Boca Raton, FL, 1982). As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from a  
35 variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats. The

immunogenicity of a Zcyto7 polypeptide may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant. A variety of assays known to those skilled in the art can be utilized to detect antibodies  
5 which specifically bind to Zcyto7 polypeptides. Exemplary assays are described in detail in *Antibodies: A Laboratory Manual*, Harlow and Lane (Eds.), (Cold Spring Harbor Laboratory Press, 1988). Representative examples of such assays include: concurrent immunoelectrophoresis, radio-  
10 immunoassays, radio-immunoprecipitations, enzyme-linked immunosorbent assays (ELISA), dot blot assays, inhibition or competition assays, and sandwich assays.

As would be evident to one of ordinary skill in  
15 the art, polyclonal antibodies can be generated by inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, hamsters, guinea pigs and rats with a Zcyto7 polypeptide or a fragment thereof. The immunogenicity of a Zcyto7  
20 polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of Zcyto7 or a portion thereof with an  
25 immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "haptent-like", such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet  
30 hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal  
35 antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab')<sub>2</sub> and Fab proteolytic fragments.

Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced.

Alternative techniques for generating or selecting antibodies useful herein include *in vitro* exposure of lymphocytes to Zcyto7 protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use of immobilized or labeled Zcyto7 protein or peptide). Genes encoding polypeptides having potential Zcyto7 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances. Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al., US

Patent NO. 5,223,409; Ladner et al., US Patent NO. 4,946,778; Ladner et al., US Patent NO. 5,403,484 and Ladner et al., US Patent NO. 5,571,698) and random peptide display libraries and kits for screening such libraries are  
5 available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA) and Pharmacia LKB Biotechnology Inc. (Piscataway, NJ). Random peptide display libraries can be screened using the Zcyto7 sequences disclosed herein  
10 to identify proteins which bind to Zcyto7. These "binding proteins" which interact with Zcyto7 polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated to drugs, toxins, radionuclides and  
15 the like. These binding proteins can also be used in analytical methods such as for screening expression libraries and neutralizing activity. The binding proteins can also be used for diagnostic assays for determining circulating levels of polypeptides; for detecting or  
20 quantitating soluble polypeptides as marker of underlying pathology or disease. These binding proteins can also act as Zcyto7 "antagonists" to block Zcyto7 binding and signal transduction *in vitro* and *in vivo*.

25           Antibodies can also be generated gene therapy. The animal is administered the DNA or RNA which encodes Zcyto7 or an immunogenic fragment thereof so that cells of the animals are transfected with the nucleic acid and express the protein which in turn elicits an immunogenic  
30 response. Antibodies which then are produced by the animal are isolated in the form of polyclonal or monoclonal antibodies.

35           Antibodies to Zcyto7 may be used for tagging cells that express the protein, for affinity purification,



within diagnostic assays for determining circulating levels of soluble protein polypeptides, and as antagonists to block ligand binding and signal transduction *in vitro* and *in vivo*.

5

Radiation hybrid mapping is a somatic cell genetic technique developed for constructing high-resolution, contiguous maps of mammalian chromosomes [Cox et al., *Science* 250:245-250 (1990)]. Partial or full knowledge of a gene's sequence allows the designing of PCR primers suitable for use with chromosomal radiation hybrid mapping panels. Commercially available radiation hybrid mapping panels which cover the entire human genome, such as the Stanford G3 RH Panel and the GeneBridge 4 RH Panel (Research Genetics, Inc., Huntsville, AL), are available. These panels enable rapid, PCR based, chromosomal localizations and ordering of genes, sequence-tagged sites (STSs), and other nonpolymorphic- and polymorphic markers within a region of interest. This includes establishing directly proportional physical distances between newly discovered genes of interest and previously mapped markers. The precise knowledge of a gene's position can be useful in a number of ways including: 1) determining if a sequence is part of an existing contig and obtaining additional surrounding genetic sequences in various forms such as YAC-, BAC- or cDNA clones, 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region, and 3) for cross-referencing model organisms such as mouse which may be beneficial in helping to determine what function a particular gene might have.

The present invention also provides reagents which will find use in diagnostic applications. For example, the *Zcyto7* gene has been mapped on chromosome 5q31. A *Zcyto7* nucleic acid probe could be used to check

35

for abnormalities on chromosome 5. For example, a probe comprising Zcyto7 DNA or RNA or a subsequence thereof can be used to determine if the Zcyto7 gene is present on chromosome 5q31 or if a mutation has occurred. Detectable  
5 chromosomal aberrations at the Zcyto7 gene locus include but are not limited to aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements. Such aberrations can be detected using polynucleotides of the present invention by employing  
10 molecular genetic techniques, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, and other genetic linkage analysis techniques known in the art [Sambrook et al., *ibid.*; Ausubel, et. al., *ibid.*; Marian, A.J., *Chest*,  
15 108: 255-265, (1995)].

Zcyto7 maps at the 5q31 region which is a "gene cluster" which contains a group of cytokines and cytokine receptors. The cytokines clustered there include IL-3, IL-  
20 4, IL-5, IL-13, GM-CSF, and M-CSF. This result authenticates zcyto7 as a cytokine.

25 The invention is further illustrated by the following non-limiting examples.

#### Example 1. Cloning of Zcyto7

30 Zcyto7 was identified from expressed sequence tag defined (EST) by SEQ ID NO: 3 by its homology to Interleukin-17. The cDNA clone was obtained from a human fetal heart cDNA library. The plasmid containing the cDNA streaked out on an LB 100 µg/ml ampicillin and 100 µg/ml  
35 methicillin plate. The cDNA insert was sequenced. The insert was determined to be 717 base pairs long with a 180

amino acid open reading frame and a putative 20 amino acid signal peptide.

### Example 2

#### Northern Blot Analysis

5 Human multiple tissue blots 1,2,3 (Clontech) were probed to determine the tissue distribution of Zcyto7. A *EcoRI/NotI* fragment containing the entire Zcyto7 coding region was generated from the EST582069 clone and used for the probe. A plasmid prep of EST582069 was prepared from a  
10 5 ml LB 100 µg/ml ampicillin overnight culture at 37° using the QIAprep Spin Miniprep Kit (Qiagen). 12 µl out of 100 µl were digested with 5 µl of H buffer (Boehringer Mannheim), 12.5 units of *EcoRI* (Gibco BRL) and 12.5 units *NotI* (New England Biolabs) in a 50 µl reaction at 37°C for 2 hours.  
15 The digest was electrophoresed on a 0.7% TBE agarose gel and the fragment was cut out. To obtain additional material the digest was repeated under the same conditions as above except 24 µl of EST582069 was used in the second digest. The second digest was electrophoresed on a 0.7% TBE agarose  
20 gel and the fragment was cut out. The DNA was extracted from both gel slabs with a QIAquick Gel Extraction Kit (Qiagen). 135 ng of this DNA was labeled with  $P^{32}$  using the Multiprime DNA Labeling System (Amersham) and unincorporated radioactivity was removed with a NucTrap  
25 Probe Purification Column (Stratagene). Multiple tissue northern blots and a human RNA master blot were prehybridized 3 hours with 10 ml ExpressHyb Solution (Clontech) containing 1 mg salmon sperm DNA which was boiled 5 minutes and then iced 1 minute and added to 10 ml of ExpressHyb Solution,  
30 mixed and added to blots. Hybridization was carried out overnight at 65°C. Initial wash conditions were as follows: 2X SSC, 0.05% SDS RT for 40 minutes with several changes of solution then 0.1X SSC, 0.1% SDS at 50°C for 40 minutes, 1 solution change. Blots were then exposed to film at -80°C for

5 hours. There was cross hybridization/background so blots were further washed at 55°C then 65°C with 0.1% X SSC, 0.1% SDS for 1 hour each. Spinal cord showed very high expression of Zcyto7 mRNA and trachea showed weak expression of mRNA. The transcript size was approximately 0.75 kb.

### Example 3

#### Chromosomal Assignment and Placement of Zcyto7.

10

Zcyto7 was mapped to chromosome 5 using the commercially available "GeneBridge 4 Radiation Hybrid Panel" (Research Genetics, Inc., Huntsville, AL). The GeneBridge 4 Radiation Hybrid Panel contains PCRable DNAs from each of 93 radiation hybrid clones, plus two control DNAs (the HFL donor and the A23 recipient). A publicly available WWW server (<http://www-genome.wi.mit.edu/cgi-bin/contig/rhmapper.pl>) allows mapping relative to the Whitehead Institute/MIT Center for Genome Research's radiation hybrid map of the human genome (the "WICGR" radiation hybrid map of the human genome) which was constructed with the GeneBridge 4 Radiation Hybrid Panel.

For the mapping of Zcyto7 with the "GeneBridge 4 RH Panel", 20 µl reactions were set up in a PCRable 96-well microtiter plate (Stratagene, La Jolla, CA) and used in a "RoboCycler Gradient 96" thermal cycler (Stratagene). Each of the 95 PCR reactions consisted of 2 µl 10X KlenTaq PCR reaction buffer (CLONTECH Laboratories, Inc., Palo Alto, CA), 1.6 µl dNTPs mix (2.5 mM each, PERKIN-ELMER, Foster City, CA), 1 µl sense primer SEQ ID NO:4, 1 µl antisense primer SEQ ID NO:5, 2 µl "RediLoad" (Research Genetics, Inc., Huntsville, AL), 0.4 µl 50X Advantage KlenTaq Polymerase Mix (Clontech Laboratories, Inc.), 25 ng of DNA

from an individual hybrid clone or control and x  $\mu$ l ddH<sub>2</sub>O for a total volume of 20  $\mu$ l. The reactions were overlaid with an equal amount of mineral oil and sealed. The PCR cyclor conditions were as follows: an initial 1 cycle 5 minute denaturation at 95°C, 35 cycles of a 1 minute denaturation at 95°C, 1 minute annealing at 52°C and 1 minute extension at 72°C, followed by a final 1 cycle extension of 7 minutes at 72°C. The reactions were separated by electrophoresis on a 3% NuSieve GTG agarose gel (FMC Bioproducts, Rockland, ME).

The results showed that Zcyto7 maps 490.89 cR from the top of the human chromosome 5 linkage group on the WICGR radiation hybrid map. Relative to the centromere, its nearest proximal marker was D5S413 and its nearest distal maker was WI-5208. The use of surrounding markers position Zcyto7 in the 5q31.3-q32 region on the integrated LDB chromosome 5 map (The Genetic Location Database, University of Southhampton, WWW server: [http://cedar.genetics.soton.ac.uk/public\\_html/](http://cedar.genetics.soton.ac.uk/public_html/)).

#### Example 4

##### Construction of Zcyto7 Expression Vectors

25

Two Zcyto7 construction vectors were made in a FLAG amino acid sequence (SEQ ID NO: 10) was inserted onto the N-terminal or C-terminal ends of the Zcyto7 polypeptide. For the construction in which the FLAG amino acid sequence was attached to the N-terminus of Zcyto7, a 473 bp Zcyto7 PCR DNA fragment was generated with 1  $\mu$ l of a ¼ dilution of the EST582069 plasmid prep of Example 2 and 20 picomoles (pm) of primer SEQ ID NO: 6 and 20 pm primer SEQ ID NO: 7. The PCR reaction was incubated at 94°C for 1 minute, and then run for 5 cycles each individual cycle being comprised of 20 seconds at 94°C and 2 minutes at 64°C.

This was followed by 22 cycles each cycle being comprised of 20 seconds at 94°C and 2 minutes at 74°C. The reaction was ended with an incubation for 10 minutes at 74°C. 50 µl of the PCR reaction mixture was digested with 30 units of *Bam*H1 (Boehringer Mannheim) and 120 units of *Xho*l (Boehringer Mannheim) for 2 hours at 37°C. The digested reaction mixture was electrophoresed on a 1% TBE gel; the DNA band was excised with a razor blade and the DNA was extracted from the gel with the Qiaquick® Gel Extraction Kit (Qiagen). The excised DNA was subcloned into plasmid nfpzp9 which had been cut with *Bam* and *Xho*. Nfpzp9 is a mammalian cell expression vector comprising an expression cassette containing the mouse metallothionein-1 promoter, a sequence encoding the tissue plasminogen activator (TPA) leader, then the FLAG peptide (SEQ ID NO:10), then multiple restriction sites. These were followed by the human growth hormone terminator, an *E. coli* origin of replication and a mammalian selectable marker expression unit containing the SV40 promoter, enhancer and origin of replication; a dihydrofolate reductase gene (DHFR) and the SV40 terminator.

For the construction of the zcyto7 gene in which a C-terminus FLAG was inserted onto the C-terminus of the zcyto7 polypeptide, a 543 bp zcyto7 PCR fragment was generated with 1 µl of ¼ dilution of the EST582069 plasmid preparation described in Example 1 and 20 pm each of primers SEQ ID NO: 8 and SEQ ID NO: 9. The PCR reaction was incubated at 94°C for 1 minute, then run for 5 cycles, each cycle being comprised 20 seconds at 94°C and 2 minutes at 55°C. This was followed by 22 cycles each cycle comprised of 20 seconds at 94°C and 2 minutes at 74°C. The reaction was ended with a final 10 minute extension at 74°C. The entire reaction mixture was run on a 1% TBE gel and the DNA was cut out with a razor blade and the DNA was extracted using the QIAQUICK™ gel extraction kit. 20 µl out of the

recovered 35 µl digested with 10 units of *Bam*H1 (Boehringer Mannheim) and 10 units of *Eco*R1 (Gibco BRL) for 2 hours at 37°C. The digested PCR mixture was electrophoresed on a 1% TBE gel. The DNA band was cut out with a razor blade and  
5 the DNA was extracted from the gel using the QIAquick® Gel Extraction Kit (Qiagen). The extracted DNA was subcloned into plasmid cfpzp9 which had been cut with *Eco*R1 and *Bam*H1. Plasmid cfpzp9 is a mammalian expression vector containing an expression cassette having the mouse  
10 metallothionein-1 promoter, multiple restriction sites for insertion of coding sequences, a sequence encoding the FLAG peptide, SEQ ID NO:10, a stop codon, a human growth hormone terminator, an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter,  
15 enhancer and origin of replication, a DHFR gene and the SV40 terminator.

Using antibodies to the FLAG polypeptides, one can separate the FLAG-tagged Zcyto7 polypeptides from a  
20 cell supernatant liquid.

#### Example 5 Cloning of murine Zcyto7

25 Mouse Zcyto7 was identified from EST SEQ ID NO:14 by its homology to human Zcyto7. The cDNA clone was discovered in a murine embryo cDNA library in which the embryos were between 13.5 and 14.5 days old. The cDNA was supplied as an agar stab containing *E. coli* transfected with the plasmid  
30 having the cDNA of interest and then streaked out on an LB 100 µg/ml ampicillin, 25 µg/ml methicillin plate. The cDNA insert in EST660242 was sequenced. The insert was determined to be 785 base pairs with an open reading frame of 180 amino acids and a putative 20 amino acid signal  
35 peptide. The sequences are defined by SEQ ID NO:11 and SEQ ID NO:12.

Example 6Tissue Distribution of murine Zcyto7

5

Mouse Multiple Tissue Northern Blot (Clontech, Palo Alto, CA), mouse northern dot blot (Clontech), a mouse embryo northern blot, and a mouse spinal cord dot blot were probed to determine the tissue distribution of murine Zcyto7.

10

The mouse embryo RNA were isolated from mouse embryos which were 6 to nine days from the date of fertilization using the POLY (A) PURE<sup>®</sup> mRNA isolation kit (Ambion). 100 mg of each mouse embryo was lysed in 1 ml of lysis buffer, homogenized and processed in batch method according to the manufacturer's protocol. For the northern blot, 2 µg of RNA was loaded on 1.5% agarose, 2.2M formaldehyde gel. The gel was run at 60V for four hours and 30 minutes. The RNA was transferred overnight onto a Nytran membrane which had been pre-wetted in 20 X SSC. The RNAs were crosslinked onto the membrane by UV light and baked at 80°C for 1 hour.

20

The mouse spinal cord RNA was also prepared with the POLY (A) PURE<sup>®</sup> mRNA isolation kit (Ambion). The mouse spinal cord dot blot was made by spotting a dot with 1, 2 and 3 µl of RNA at 1µg RNA/µl concentration onto Nytran membrane.

25

A Not1/EcoRI fragment containing the entire Zcyto7 coding region was generated from the clone containing SEQ ID NO: 12 (hereinafter referred to as the SEQ ID NO:12 clone) and was used for the probe. A plasmid prep of the SEQ ID NO:12 clone was prepared from a 5 ml LB 100 µg/ml ampicillin overnight culture at 37°C using the QIAPREP SPIN MINIPREP kit (Qiagen). 4.66 µg were digested with 8 µl of

30

35



high buffer (Boehringer Mannheim), 20 units of NotI (Biolabs) and 20 units of EcoRI (Gibco BRL) in a 80 µl reaction at 37°C for 2 hours. The digest was electrophoresed on a 1.0% TBE gel and the fragment was cut out. The DNA was  
5 extracted from the gel slab with a QIAQUICK® gel extraction kit (Qiagen). 98.8 ng of this fragment was labeled with P<sup>32</sup> using the MULTIMPRIME® DNA labeling system (Amersham) and unincorporated radioactivity was removed with a NUCTRAP® probe purification column (Stratagene).

10

The two northern preps and the two dot blot preps were prehybridized for 3 hours at 65°C as follows. 1 mg of salmon sperm was boiled 5 minutes, iced 1 minute, mixed with 10 ml of EXPRESSHYB® solution and added to the blots.

15 Hybridization was carried out overnight at 65°C. Initial wash conditions were as follows: 2 X SSC, 0.1% SDS for 40 minutes at room temperature then 0.1 X SSC, 0.1% SDS for 40 minutes at 50°C. Blots were exposed to film overnight at -80°C. The northern blots and the mouse dot blot were further  
20 washed with 0.1% X SSC, 0.1% SDS at 60°C to remove background. The mouse spinal cord dot blot was washed again at higher stringency with 0.1 X SSC, 0.1% SDS at 65°C to confirm the earlier results.

25 Results: Mouse Zcyto7 expression was seen in the spinal cord, submaxillary gland and epididymis. Mouse embryo showed expression of Zcyto7 starting on day 12, peaking at day 16 and ending day 17 from the date of fertilization. The transcript size was approximately 1 kb.

30

Example 7Proliferation of Chondrocytes Using Zcyto7

5 A chondrocyte proliferation assay was done to  
determine the effect that Zcyto7 would have on chondrocyte  
proliferation. The assay was done with 20% confluent  
cultures. As a control vehicle, bovine serum albumin was  
added to a culture of chondrocytes instead of Zcyto7. The  
10 assay measured the 3H-thymidine incorporation of nascent  
DNA in the chondrocytes, Wahl et al., *Mol. Cell. Biol.*  
8:5016-5025 (1988).

Results: A 3.5 - 9 fold stimulation of primary chondrocyte  
15 proliferation was seen upon exposure of the chondrocyte  
cultures to 1µg/ml of zcyto7. Chondrocyte stimulation by  
zcyto7 was seen with multiple preparations of the protein  
and was seen across species lines. In contrast to this, the  
control experiment using BSA resulted in no stimulation of  
20 chondrocytes.

Example 8

25 Production of Glycosaminoglycan by Zcyto7-treated  
Chondrocytes

A 20% confluent culture of chondrocytes was prepared  
and zcyto7 was applied at a concentration of 1µg/ml. In a  
second experiment in addition to zcyto7, IL-1β was applied  
30 to the cell culture. In a control group BSA was added to  
the chondrocyte culture. The level of glycosaminoglycan  
(GAG) production by the chondrocyte culture was then  
determined using a 1,9-dimethylmethylene blue dye binding  
assay, Fardale et al., *Biochem. Biophys. Acta* 888:173-177  
35 (1987).

Results: Chondrocytes which were cultured with zcyto7 showed a 50% increase in the steady state presence of GAG in the chondrocyte culture. Moreover, when the chondrocytes were co-cultured with both zcyto7 and interleukin-1 $\beta$  (IL-1) the GAG production by the chondrocytes increased 2.5 fold as compared with culturing of the chondrocytes with either zcyto7 or IL-1 $\beta$  alone. While the cultured cells to which BSA was added showed no increased production of GAG.

10

#### Example 9

##### Osteoblast Stimulation by Zcyto7

15 The CCC4 cell line is an osteoblast-like cell line derived from p53 knockout mice. The CCC4 line was transfected with a plasmid containing an inducible serum response element (SRE) driving the expression of luciferase. The stimulation of the SRE and thus the expression of luciferase indicates that the chemical entity is likely to stimulate osteoblasts.

CCC4 cells were cultured in the presence of 1 $\mu$ g of zcyto7/ml of culture medium. As a control BSA, fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) were each added to different cultures of CCC4 cells. BSA was a negative control and FGF and PDGF were positive controls as they are known to promote osteoblast proliferation. Luciferase activity was detected by addition of 40  $\mu$ l of Promega luciferase substrate using a 2 second integrated read on Labsystes LUMINOSKAN<sup>®</sup>.

30

#### Results

Zcyto7 as well as, FGF and PDGF stimulate the expression of luciferase in this assay indicating that they

35

stimulate osteoblasts. The BSA vehicle control was negative in this assay.

#### Example 10

5

##### Effect of Zcyto7 on the Growth of Fibroblasts

Confluent cultures of human dermal, lung, and fetal lung fibroblasts were inoculated with Zcyto7 to determine the effects of Zcyto7 on the growth of fibroblasts. FGF was used as a positive control and BSA as a negative control vehicle.

Results: Zcyto7 had no effect on the growth of fibroblasts.

15

#### Example 11

##### Effect of Zcyto7 on the Growth of BaF3 Cells

BaF3 cells, a murine pre-B cell line dependent on IL-3 to proliferate, were washed several times with base medium and then plated in a 96-well plate each well contained approximately 5500 cells/well. The cells were treated with either 1µg/ml of Zcyto7 or 1-2pg/ml of IL-3 or with a combination of both Zcyto7 and IL-3. Also in a separate experiment 0.1-10ng/ml of TGFβ was added to the wells instead of Zcyto7. After incubation of the assay plate at 37°C and 5% CO<sub>2</sub> for 3-6 days, 20 µl of ALAMAR blue was added to each well and the plate is incubated at 37° C for 15-24 hours. The plate was then read with a fluorometer with excitation wavelength of 544m and emission wavelength of 590m. The assay was also scored by eye for stimulation or inhibition of cell proliferation prior to the addition of the ALAMAR blue. The base medium contained RPMI 1640 + 10% HIA-FBS + L-glutamine + Na pyruvate.

Results: Zcyto7 and TGF $\beta$  significantly inhibited the IL-3 driven proliferation of BaF3 cells. However, when neutralizing antibodies to TGF $\beta$  were added in along with the Zcyto7, the Zcyto7 inhibition of the proliferation of the BaF3 cells was eliminated.

#### Example 12

##### Effect of Zcyto7 on the Growth of TF-1 Cells

10

TF-1 cells, a human leukemia cell line which is GM-CSF or IL-1 $\beta$  dependent, were washed several times with base medium and then plated in a 96-well plate each well containing approximately 7000 cells/well. The cells were co-cultured with 1 $\mu$ g/ml of Zcyto7 and 100-200pg/ml of IL-1 $\beta$ . Also in a separate experiment TGF $\beta$  was added to the wells instead of Zcyto7. After incubation of the assay plate at 37°C and 5% CO<sub>2</sub> for 3-6 days, 20  $\mu$ l of ALAMAR blue was added to each well and the plate is incubated at 37° C for 15-24 hours. The plate is then read with a fluorometer with excitation wavelength of 544nm and emission wavelength of 590nm. The assay was also scored by eye for stimulation or inhibition of cell proliferation prior to the addition of the ALAMAR blue. The base medium contained RPMI 1640 + 10% HIA-FBS + L-glutamine + Na pyruvate.

Results: The IL-1 $\beta$  stimulation of TF-1 cells is inhibited by both Zcyto7 and TGF- $\beta$ . The concentration of Zcyto7 at which inhibition of proliferation occurred was greater than 200ng/ml; and the concentration of TGF- $\beta$  at which inhibition of proliferation occurred was about 50pg/ml.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: ZymoGenetics, Inc.  
1201 Eastlake Avenue East  
Seattle  
WA  
USA  
98102
- (ii) TITLE OF THE INVENTION: MAMMALIAN CYTOKINE-LIKE FACTOR-7
- (iii) NUMBER OF SEQUENCES: 43
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: ZymoGenetics, Inc.
  - (B) STREET: 1201 Eastlake Avenue East
  - (C) CITY: Seattle
  - (D) STATE: WA
  - (E) COUNTRY: USA
  - (F) ZIP: 98102
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette
  - (B) COMPUTER: IBM Compatible
  - (C) OPERATING SYSTEM: DOS
  - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Lunn, Paul G
  - (B) REGISTRATION NUMBER: 32,743
  - (C) REFERENCE/DOCKET NUMBER: 97-15PC

## (ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 206-442-6627
- (B) TELEFAX: 206-442-6678
- (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 736 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 57...596
- (D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAATTCGGCA CGAGGAGGCG GGCAGCAGCT GCAGGCTGAC CTTGCAGCTT GGC GGA ATG	59
Met	
1	
GAC TGG CCT CAC AAC CTG CTG TTT CTT CTT ACC ATT TCC ATC TTC CTG	107
Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe Leu	
5 10 15	
GGG CTG GGC CAG CCC AGG AGC CCC AAA AGC AAG AGG AAG GGG CAA GGG	155
Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly	
20 25 30	
CGG CCT GGG CCC CTG GCC CCT GGC CCT CAC CAG GTG CCA CTG GAC CTG	203
Arg Pro Gly Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu	
35 40 45	
GTG TCA CGG ATG AAA CCG TAT GCC CGC ATG GAG GAG TAT GAG AGG AAC	251
Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn	
50 55 60 65	

54

ATC GAG GAG ATG GTG GCC CAG CTG AGG AAC AGC TCA GAG CTG GCC CAG Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln 70 75 80	299
AGA AAG TGT GAG GTC AAC TTG CAG CTG TGG ATG TCC AAC AAG AGG AGC Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser 85 90 95	347
CTG TCT CCC TGG GGC TAC AGC ATC AAC CAC GAC CCC AGC CGT ATC CCC Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro 100 105 110	395
GTG GAC CTG CCG GAG GCA CGG TGC CTG TGT CTG GGC TGT GTG AAC CCC Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro 115 120 125	443
TTC ACC ATG CAG GAG GAC CGC AGC ATG GTG AGC GTG CCG GTG TTC AGC Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser 130 135 140 145	491
CAG GTT CCT GTG CGC CGC CGC CTC TGC CCG CCA CCG CCC CGC ACA GGG Gln Val Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly 150 155 160	539
CCT TGC CGC CAG CGC GCA GTC ATG GAG ACC ATC GCT GTG GGC TGC ACC Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr 165 170 175	587
TGC ATC TTC TGAATCACCT GGCCAGAAAG CCAGGCCAGC AGCCCGAGAC CATCCTCCT Cys Ile Phe 180	645
TGCACCTTTG TGCCAAGAAA GGCCTATGAA AAGTAAACAC TGACTTTTGA AAGCCAGAAA AAAAAAAAAA AAAAAAATT CCTGCGGCCG C	705 736

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 180 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (v) FRAGMENT TYPE: internal



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile Phe  
 1 5 10 15  
 Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln  
 20 25 30  
 Gly Arg Pro Gly Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp  
 35 40 45  
 Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg  
 50 55 60  
 Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala  
 65 70 75 80  
 Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg  
 85 90 95  
 Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile  
 100 105 110  
 Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn  
 115 120 125  
 Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe  
 130 135 140  
 Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr  
 145 150 155 160  
 Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys  
 165 170 175  
 Thr Cys Ile Phe  
 180

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 397 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AGGCGGGCAN AGCTGCAGGC TGACCTTGCA GCTTGGCGGA ATGGACTGGC CTCACAACCT 60  
 GCTGTTTCTT CTTACCATTT CCATCTTCCT GGGGCTGGGC AGCCAGGAGC CCCAAAAGCA 120  
 AGAGGAAGGG GCAAGGGCGG CCTGGGCCCN TGGCCTGGCC TCACCAGGTG CCACTGGACC 180  
 TGGTGTACAG GATGAAACCG TATGCCCGCA TGGAGGAGTA TGAGAGGAAC ATCGAGGAGA 240  
 TGGTGGCCCA GCTGAGGAAC AGCTCANAAG CTGGCCCGA GAAAGTGTGA GGTCAACTTG 300

56

CAGCTGTGGA TGTCCAACAA GAAGGAGCCT GTCTCCCTTG GGGCTACAAG CATCAACCAC 360  
CGACCCCAGC CGTATCCCCG TGGGACCTTG CCGGGAC 397

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: ZC13265

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTACCATTTC CATCTTCC

18

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: ZC13266

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCCTTCCTCT TGCTTTTG

18

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: Other

## (vii) IMMEDIATE SOURCE:

57

(B) CLONE: ZC13326

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CAAGGATCCC AGCCCAGGAG CCCCAAAAG

29

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(vii) IMMEDIATE SOURCE:

(B) CLONE: ZC13330

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GACCTCGAGT CAGAAGATGC AGGTGCAGCC

30

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(vii) IMMEDIATE SOURCE:

(B) CLONE: ZC13325

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GTCGAATTCA TGGACTGGCC TCACAACCTG

30

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

58

(ii) MOLECULE TYPE: Other

(vii) IMMEDIATE SOURCE:

(B) CLONE: ZC13327

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GAAGGATCCG AAGATGCAGG TGCAGCC

27

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Asp	Tyr	Lys	Asp	Asp	Asp	Lys	Gly	Ser
1			5				10	

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 692 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 50...589

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGGGTTCCTG	GCGGGTGGCA	GCTGCGGGCC	TGCCGCCTGA	CTTGGTGGG	ATG	GAC	TGG	58
					Met	Asp	Trp	
					1			

CCG CAC AGC CTG CTC TTC CTC CTG GCC ATC TCC ATC TTC CTG GCG CCA Pro His Ser Leu Leu Phe Leu Leu Ala Ile Ser Ile Phe Leu Ala Pro 5 10 15	106
AGC CAC CCC CGG AAC ACC AAA GGC AAA AGA AAA GGG CAA GGG AGG CCC Ser His Pro Arg Asn Thr Lys Gly Lys Arg Lys Gly Gln Gly Arg Pro 20 25 30 35	154
AGT CCC TTG GCC CCT GGG CCT CAT CAG GTG CCG CTG GAC CTG GTG TCT Ser Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser 40 45 50	202
CGA GTA AAG CCC TAC GCT CGA ATG GAA GAG TAT GAG CGG AAC CTT GGG Arg Val Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Leu Gly 55 60 65	250
GAG ATG GTG GCC CAG CTG AGG AAC AGC TCC GAG CCA GCC AAG AAG AAA Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala Lys Lys Lys 70 75 80	298
TGT GAA GTC AAT CTA CAG CTG TGG TTG TCC AAC AAG AGG AGC CTG TCC Cys Glu Val Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg Ser Leu Ser 85 90 95	346
CCA TGG GGC TAC AGC ATC AAC CAC GAC CCC AGC CGC ATC CCT GCG GAC Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Ala Asp 100 105 110 115	394
TTG CCC GAG GCG CGG TGC CTA TGT TTG GGT TGC GTG AAT CCC TTC ACC Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr 120 125 130	442
ATG CAG GAG GAC CGT AGC ATG GTG AGC GTG CCA GTG TTC AGC CAG GTG Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val 135 140 145	490
CCG GTG CGC CGC CGC CTC TGT CCT CAA CCT CCT CGC CCT GGG CCC TGC Pro Val Arg Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro Gly Pro Cys 150 155 160	538
CGC CAG CGT GTC GTC ATG GAG ACC ATC GCT GTG GGT TGC ACC TGC ATC Arg Gln Arg Val Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile 165 170 175	586

TTC TGAGCCAACC ACCAACCCGG TGGCCTCTGC AACAAACCCTC CCTCCCTGCA CCCACT 645

Phe

180-

GTGACCCTCA AGGCTGATAA ACAGTAAACG CTGTTCTTTG TAAAGGA

692

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 180 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met	Asp	Trp	Pro	His	Ser	Leu	Leu	Phe	Leu	Leu	Ala	Ile	Ser	Ile	Phe
1				5				10					15		
Leu	Ala	Pro	Ser	His	Pro	Arg	Asn	Thr	Lys	Gly	Lys	Arg	Lys	Gly	Gln
		20					25					30			
Gly	Arg	Pro	Ser	Pro	Leu	Ala	Pro	Gly	Pro	His	Gln	Val	Pro	Leu	Asp
		35				40					45				
Leu	Val	Ser	Arg	Val	Lys	Pro	Tyr	Ala	Arg	Met	Glu	Glu	Tyr	Glu	Arg
	50				55			60							
Asn	Leu	Gly	Glu	Met	Val	Ala	Gln	Leu	Arg	Asn	Ser	Ser	Glu	Pro	Ala
65				70				75					80		
Lys	Lys	Lys	Cys	Glu	Val	Asn	Leu	Gln	Leu	Trp	Leu	Ser	Asn	Lys	Arg
		85					90					95			
Ser	Leu	Ser	Pro	Trp	Gly	Tyr	Ser	Ile	Asn	His	Asp	Pro	Ser	Arg	Ile
		100					105					110			
Pro	Ala	Asp	Leu	Pro	Glu	Ala	Arg	Cys	Leu	Cys	Leu	Gly	Cys	Val	Asn
	115					120					125				
Pro	Phe	Thr	Met	Gln	Glu	Asp	Arg	Ser	Met	Val	Ser	Val	Pro	Val	Phe
	130					135					140				
Ser	Gln	Val	Pro	Val	Arg	Arg	Arg	Leu	Cys	Pro	Gln	Pro	Pro	Arg	Pro
145				150				155					160		
Gly	Pro	Cys	Arg	Gln	Arg	Val	Val	Met	Glu	Thr	Ile	Ala	Val	Gly	Cys
			165					170						175	
Thr	Cys	Ile	Phe												
		180													

(2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 497 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

GGGGTTCCTG GCGGGTGGCA GCTGCGGGCC TGCCGCCTGA CTTGGTGGGA TGGACTGGCC   60
GCACAGCCTG CTCTTCCTCC TGGCCATCTC CATCTTCCTG GCGCCAAGCC ACCCCCGGAA   120
CACCAAAGGC AAAAGAAAAG GGCAAGGGAG GCCCAGTCCC TTGGCCCCTG GGCTCATCAG   180
GTGCCGCTGG ACCTGGTGTC TCGAGTAAAG CCCTACGCTC GAATGGAAGA GTATGAGCGG   240
AACCTTGGGG AGATGGTGGC CCAGCTGAGG AACAGCTCCG AGCCAGCCAA GAAGAAATGT   300
GAAGTCAATC TACAGCTGTG GTTGTCCAAC AAGAGGAGCC TGTCCCCATG GGGCTACAGC   360
ATCAACCACG ACCCCAGCCG CATCCCTGCG GACTTGCCCG AGGCGCGGTG CCTATGTTTG   420
GGTTGCGTGA ATCCCTTCAC CATGCAGGAG GACCGTAGCA TGGTGAGCGT GCCAGTGTTT   480
AGCCAGGTGC CGGTGCG                                     497

```

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```

Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly
 1           5           10           15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg
 20           25           30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
 35           40           45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
 50           55           60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
 65           70           75           80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
 85           90           95

```

62

```

Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
      100                      105                      110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
      115                      120                      125
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
      130                      135                      140
Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
145                      150                      155                      160

```

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```

Gln Pro Arg Ala Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly
1      5      10      15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg
      20      25      30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
      35      40      45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
      50      55      60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
65      70      75      80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
      85      90      95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
      100      105      110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
      115      120      125
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
      130      135      140
Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
145      150      155      160

```

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:



63

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```

Gln Pro Arg Ser Pro Lys Ala Lys Arg Lys Gly Gln Gly Arg Pro Gly
1      5      10      15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg
20      25      30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
35      40      45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
50      55      60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
65      70      75      80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
85      90      95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
100     105     110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
115     120     125
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
130     135     140
Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
145     150     155     160

```

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```

Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Ala
1      5      10      15

```

64

```

Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg
      20              25              30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
      35              40              45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
      50              55              60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
      65              70              75              80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
      85              90              95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
      100             105             110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
      115             120             125
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
      130             135             140
Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
      145             150             155             160

```

## (2) INFORMATION FOR SEQ ID NO:18:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

```

Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly
1              5              10              15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ala Arg
      20              25              30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
      35              40              45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
      50              55              60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
      65              70              75              80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
      85              90              95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
      100             105             110

```

65

Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro  
           115                          120                          125  
 Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg  
           130                          135                          140  
 Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe  
   145                          150                          155                          160

## (2) INFORMATION FOR SEQ ID NO:19:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly  
   1                          5                          10                          15  
 Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg  
           20                          25                          30  
 Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu  
           35                          40                          45  
 Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys  
           50                          55                          60  
 Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro  
   65                          70                          75                          80  
 Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu  
           85                          90                          95  
 Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met  
           100                          105                          110  
 Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro  
           115                          120                          125  
 Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg  
           130                          135                          140  
 Gln Arg Val Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe  
   145                          150                          155                          160

## (2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```

Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly
 1           5           10          15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg
      20           25           30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
      35           40           45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
      50           55           60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
65           70           75           80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
      85           90           95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
      100          105          110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
      115          120          125
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
      130          135          140
Gln Arg Leu Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
145          150          155          160

```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 160 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```

Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly
 1           5           10          15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg
      20           25           30

```

67

```

Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
   35           40           45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
   50           55           60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
  65           70           75           80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
           85           90           95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
   100          105          110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
   115          120          125
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
   130          135          140
Gln Arg Phe Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
  145          150          155          160

```

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```

Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly
 1           5           10           15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Gly Arg
   20           25           30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
   35           40           45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
   50           55           60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
  65           70           75           80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
           85           90           95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
   100          105          110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
   115          120          125

```

Val	Arg	Arg	Arg	Leu	Cys	Pro	Pro	Pro	Pro	Arg	Thr	Gly	Pro	Cys	Arg
130						135						140			
Gln	Arg	Ala	Val	Met	Glu	Thr	Ile	Ala	Val	Gly	Cys	Thr	Cys	Ile	Phe
145					150					155					160

## (2) INFORMATION FOR SEQ ID NO:23:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Gln	Pro	Arg	Ser	Pro	Lys	Ser	Lys	Arg	Lys	Gly	Gln	Gly	Arg	Pro	Ser
1				5					10					15	
Pro	Leu	Ala	Pro	Gly	Pro	His	Gln	Val	Pro	Leu	Asp	Leu	Val	Ser	Arg
			20				25						30		
Met	Lys	Pro	Tyr	Ala	Arg	Met	Glu	Glu	Tyr	Glu	Arg	Asn	Ile	Glu	Glu
	35					40						45			
Met	Val	Ala	Gln	Leu	Arg	Asn	Ser	Ser	Glu	Leu	Ala	Gln	Arg	Lys	Cys
	50					55					60				
Glu	Val	Asn	Leu	Gln	Leu	Trp	Met	Ser	Asn	Lys	Arg	Ser	Leu	Ser	Pro
65					70					75				80	
Trp	Gly	Tyr	Ser	Ile	Asn	His	Asp	Pro	Ser	Arg	Ile	Pro	Val	Asp	Leu
			85						90					95	
Pro	Glu	Ala	Arg	Cys	Leu	Cys	Leu	Gly	Cys	Val	Asn	Pro	Phe	Thr	Met
			100					105						110	
Gln	Glu	Asp	Arg	Ser	Met	Val	Ser	Val	Pro	Val	Phe	Ser	Gln	Val	Pro
	115						120					125			
Val	Arg	Arg	Arg	Leu	Cys	Pro	Pro	Pro	Pro	Arg	Thr	Gly	Pro	Cys	Arg
	130					135					140				
Gln	Arg	Ala	Val	Met	Glu	Thr	Ile	Ala	Val	Gly	Cys	Thr	Cys	Ile	Phe
145					150					155					160

## (2) INFORMATION FOR SEQ ID NO:24:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```

Gln Pro Arg Ser Pro Lys Val Lys Arg Lys Gly Gln Gly Arg Pro Gly
 1           5           10           15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg
 20           25           30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
 35           40           45
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
 50           55           60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
 65           70           75           80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
 85           90           95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
100           105           110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
115           120           125
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
130           135           140
Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
145           150           155           160

```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```

Gln Pro Arg Val Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly
 1           5           10           15
Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg
 20           25           30
Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
 35           40           45

```

70

```

Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
 50          55          60
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
65          70          75          80
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
          85          90          95
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
          100          105          110
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
          115          120          125
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
          130          135          140
Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
145          150          155          160

```

## (2) INFORMATION FOR SEQ ID NO:26:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 97 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```

Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser
 1          5          10          15
Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp
          20          25          30
Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr
          35          40          45
Met Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val
          50          55          60
Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys
65          70          75          80
Arg Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile
          85          90          95
Phe

```

## (2) INFORMATION FOR SEQ ID NO:27:

## (i) SEQUENCE CHARACTERISTICS:



- (A) LENGTH: 100 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

```

Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly Pro
 1           5           10           15
Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg Met
      20           25           30
Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu Met
      35           40           45
Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys Glu
      50           55           60
Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro Trp
      65           70           75           80
Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu Pro
      85           90           95
Glu Ala Arg Cys
      100

```

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```

Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly Pro
 1           5           10           15
Leu

```

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids

72

- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu  
1 5 10 15  
Glu

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu Pro Glu Ala Arg Cys  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Pro Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys  
1 5 10 15  
Arg Gln Arg

## (2) INFORMATION FOR SEQ ID NO:32:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

```

Pro Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly Pro
 1             5             10             15
Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg Met
      20             25             30
Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
      35             40             45

```

## (2) INFORMATION FOR SEQ ID NO:33:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 70 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```

Arg Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu
 1             5             10             15
Glu Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys
      20             25             30
Cys Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser
      35             40             45
Pro Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp
      50             55             60
Leu Pro Glu Ala Arg Cys
65             70

```

## (2) INFORMATION FOR SEQ ID NO:34:

## (i) SEQUENCE CHARACTERISTICS:

74

- (A) LENGTH: 61 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

```

Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu Pro Glu Ala Arg Cys
 1           5           10           15
Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met Gln Glu Asp Arg Ser
          20          25          30
Met Val Ser Val Pro Val Phe Ser Gln Val Pro Val Arg Arg Arg Leu
          35          40          45
Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg Gln Arg
 50          55          60

```

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 73 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

```

Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu Pro Glu Ala Arg Cys
 1           5           10           15
Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met Gln Glu Asp Arg Ser
          20          25          30
Met Val Ser Val Pro Val Phe Ser Gln Val Pro Val Arg Arg Arg Leu
          35          40          45
Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg Gln Arg Ala Val Met
 50          55          60
Glu Thr Ile Ala Val Gly Cys Thr Cys
 65          70

```

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 158 amino acids

75

- (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

```

Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly Pro Leu
 1           5           10          15
Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg Met Lys
 20          25          30
Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu Met Val
 35          40          45
Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys Glu Val
 50          55          60
Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro Trp Gly
 65          70          75          80
Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu Pro Glu
 85          90          95
Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met Gln Glu
100         105         110
Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro Val Arg
115         120         125
Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg Gln Arg
130         135         140
Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
145         150         155

```

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 154 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

```

Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly Pro Leu Ala Pro Gly Pro
 1           5           10          15
His Gln Val Pro Leu Asp Leu Val Ser Arg Met Lys Pro Tyr Ala Arg
 20          25          30

```

76

```

Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu Met Val Ala Gln Leu Arg
   35         40         45
Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys Glu Val Asn Leu Gln Leu
   50         55         60
Trp Met Ser Asn Lys Arg Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn
   65         70         75         80
His Asp Pro Ser Arg Ile Pro Val Asp Leu Pro Glu Ala Arg Cys Leu
           85         90         95
Cys Leu Gly Cys Val Asn Pro Phe Thr Met Gln Glu Asp Arg Ser Met
       100       105       110
Val Ser Val Pro Val Phe Ser Gln Val Pro Val Arg Arg Arg Leu Cys
       115       120       125
Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg Gln Arg Ala Val Met Glu
       130       135       140
Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
145         150

```

## (2) INFORMATION FOR SEQ ID NO:38:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

```

Lys Gly Gln Gly Arg Pro Gly Pro Leu Ala Pro Gly Pro His Gln Val
 1         5         10         15
Pro Leu Asp Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu Glu
 20        25        30
Tyr Glu Arg Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn Ser Ser
 35        40        45
Glu Leu Ala Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp Met Ser
 50        55        60
Asn Lys Arg Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His Asp Pro
 65        70        75        80
Ser Arg Ile Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys Leu Gly
           85         90         95
Cys Val Asn Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val Ser Val
       100       105       110
Pro Val Phe Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro Pro Pro
       115       120       125

```

77

Pro Arg Thr Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr Ile Ala  
 130 135 140  
 Val Gly Cys Thr Cys Ile Phe  
 145 150

## (2) INFORMATION FOR SEQ ID NO:39:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 160 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

His Pro Arg Asn Thr Lys Gly Lys Arg Lys Gly Gln Gly Arg Pro Ser  
 1 5 10 15  
 Pro Leu Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg  
 20 25 30  
 Val Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Leu Gly Glu  
 35 40 45  
 Met Val Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala Lys Lys Lys Cys  
 50 55 60  
 Glu Val Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg Ser Leu Ser Pro  
 65 70 75 80  
 Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Ala Asp Leu  
 85 90 95  
 Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met  
 100 105 110  
 Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro  
 115 120 125  
 Val Arg Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro Gly Pro Cys Arg  
 130 135 140  
 Gln Arg Val Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe  
 145 150 155 160

## (2) INFORMATION FOR SEQ ID NO:40:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 158 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

```

Arg Asn Thr Lys Gly Lys Arg Lys Gly Gln Gly Arg Pro Ser Pro Leu
 1           5           10           15
Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg Val Lys
      20           25           30
Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Leu Gly Glu Met Val
      35           40           45
Ala Gln Leu Arg Asn Ser Ser Glu Pro Ala Lys Lys Lys Cys Glu Val
      50           55           60
Asn Leu Gln Leu Trp Leu Ser Asn Lys Arg Ser Leu Ser Pro Trp Gly
      65           70           75           80
Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Ala Asp Leu Pro Glu
      85           90           95
Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met Gln Glu
      100          105          110
Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro Val Arg
      115          120          125
Arg Arg Leu Cys Pro Gln Pro Pro Arg Pro Gly Pro Cys Arg Gln Arg
      130          135          140
Val Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
      145          150          155

```

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 153 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

```

Lys Arg Lys Gly Gln Gly Arg Pro Gly Pro Leu Ala Pro Gly Pro His
 1           5           10           15
Gln Val Pro Leu Asp Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met
      20           25           30
Glu Glu Tyr Glu Arg Asn Ile Glu Glu Met Val Ala Gln Leu Arg Asn
      35           40           45

```



79

```

Ser Ser Glu Leu Ala Gln Arg Lys Cys Glu Val Asn Leu Gln Leu Trp
 50          55          60
Met Ser Asn Lys Arg Ser Leu Ser Pro Trp Gly Tyr Ser Ile Asn His
65          70          75          80
Asp Pro Ser Arg Ile Pro Val Asp Leu Pro Glu Ala Arg Cys Leu Cys
          85          90          95
Leu Gly Cys Val Asn Pro Phe Thr Met Gln Glu Asp Arg Ser Met Val
          100          105          110
Ser Val Pro Val Phe Ser Gln Val Pro Val Arg Arg Arg Leu Cys Pro
          115          120          125
Pro Pro Pro Arg Thr Gly Pro Cys Arg Gln Arg Ala Val Met Glu Thr
          130          135          140
Ile Ala Val Gly Cys Thr Cys Ile Phe
145          150

```

## (2) INFORMATION FOR SEQ ID NO:42:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 128 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

```

Met Lys Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu
 1          5          10          15
Met Val Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys
          20          25          30
Glu Val Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
          35          40          45
Trp Gly Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
          50          55          60
Pro Glu Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met
          65          70          75          80
Gln Glu Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro
          85          90          95
Val Arg Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg
          100          105          110
Gln Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe
          115          120          125

```

## (2) INFORMATION FOR SEQ ID NO:43:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 157 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

```

Arg Ser Pro Lys Ser Lys Arg Lys Gly Gln Gly Arg Pro Gly Pro Leu
 1           5           10          15
Ala Pro Gly Pro His Gln Val Pro Leu Asp Leu Val Ser Arg Met Lys
 20          25          30
Pro Tyr Ala Arg Met Glu Glu Tyr Glu Arg Asn Ile Glu Glu Met Val
 35          40          45
Ala Gln Leu Arg Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys Glu Val
 50          55          60
Asn Leu Gln Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro Trp Gly
 65          70          75          80
Tyr Ser Ile Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu Pro Glu
 85          90          95
Ala Arg Cys Leu Cys Leu Gly Cys Val Asn Pro Phe Thr Met Gln Glu
100         105         110
Asp Arg Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro Val Arg
115         120         125
Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg Gln Arg
130         135         140
Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile
145         150         155

```

## CLAIMS.

We claim:

1. An isolated polynucleotide which encodes a mammalian Zcyto7 polypeptide or variants thereof.
2. The isolated polynucleotide of claim 1 wherein said polynucleotide encodes a polypeptide selected from the group SEQ ID NO:2, SEQ ID NO:12, SEQ ID NOS:14-27 and SEQ ID NOS: 36-43.
3. A polynucleotide of claim 2 wherein the polypeptide encoded by said polynucleotide is a polypeptide defined by SEQ ID NOS: 15-25 wherein the amino termini of said polypeptides begin at either amino acid residue 3, an arginine; amino acid residue 7, a serine; amino acid residue 8, a lysine; amino acid residue 10, a lysine or amino acid residue 33 methionine.
4. A polynucleotide of claim 2 wherein the polypeptide encoded by said polynucleotide is a polypeptide defined by SEQ ID NOS: 2, 12, 14-25 and 36 to 42 wherein the amino acid sequences end at the isoleucines at amino acid residue 179 of SEQ ID NO: 2, at amino acid residue 159 of SEQ ID NOS: 14-25, which corresponds to amino acid residue 157 of SEQ ID NO:36, amino acid residue 153 of SEQ ID NO:37, amino acid residue 150 of SEQ ID NO:38, amino acid residue 159 of SEQ ID NO: 39, amino acid residue 157 of SEQ ID NO:40, amino acid residue 152 SEQ ID NO:42, amino acid residue 127 of SEQ ID NO:42.
5. An isolated polynucleotide which encodes a peptide or polypeptide having at least 15 amino acid residues comprised of an epitope-bearing portion of a polypeptide of SEQ ID NOS: 2, 14-27 and 36-43.

6. The isolated polynucleotide of claim 5 wherein the peptide or polypeptide is selected from the group consisting of SEQ ID NOs:28-35.

7. The polynucleotide of claims 5 or 6 wherein peptide or polypeptide is fused to a carrier polypeptide or other carrier molecule.

8. A polynucleotide of which encodes a peptide or polypeptide which is 90%, 95% or 99% identical to the polypeptides encoded by the polynucleotides of claims 1-7.

9. An expression vector comprising the following operably linked elements:

a transcription promoter;

a DNA segment defined by claims 1-8; and

a transcription terminator.

10. An expression vector comprising the following operably linked elements:

(a) a transcription promoter;

(b) a DNA segment encoding a chimeric polypeptide, wherein said chimeric polypeptide consists essentially of a first portion and a second portion joined by a peptide bond, said first portion being comprised of a mammalian polypeptide, said polypeptide being the amino acid sequences of SEQ ID NOs: 2,12, 14-43 and said second portion being a second polypeptide or protein.

(c) a transcription terminator.

11. An isolated mammalian Zcyto7 polypeptide or variants thereof.

12. The isolated Zcyto7 polypeptide of claim 11 selected from the group of amino acid sequences consisting of SEQ ID NOS: 2, 12, 14-27 and 36-43.

13. A polypeptide of claim 12 wherein the polypeptide is a polypeptide defined by SEQ ID NOS: 15-25 wherein the amino termini of said polypeptides are modified and begin at either amino acid residue 3, an arginine; amino acid residue 7, a serine; amino acid residue 8, a lysine; amino acid residue 10, a lysine or amino acid residue 33 methionine.

14. A polypeptide of claim 12 wherein the polypeptide is a polypeptide defined by SEQ ID NOS: 2, 12, 14-25 and 36 to 42 wherein the amino acid sequences end at the isoleucines at amino acid residue 179 of SEQ ID NO: 2, at amino acid residue 159 of SEQ ID NOS: 14-25, which corresponds to amino acid residue 157 of SEQ ID NO:36, amino acid residue 153 of SEQ ID NO:37, amino acid residue 150 of SEQ ID NO:38, amino acid residue 159 of SEQ ID NO: 39, amino acid residue 157 of SEQ ID NO:40, amino acid residue 152 SEQ ID NO:42, amino acid residue 127 of SEQ ID NO:42.

15. An isolated peptide or polypeptide having at least 15 amino acid residues comprised of an epitope-bearing portion of a polypeptide of a Zcyto7 polypeptide.

16. The peptide or polypeptide of claim 15 wherein said peptide or polypeptide is an epitope-bearing portion of a polypeptide of SEQ ID NOS: 2, 14-27 and 36-43.

17. The isolated peptide or polypeptide of claim 16 wherein the peptide or polypeptide is selected from the group of amino acid sequence consisting of SEQ ID NOS:28-35.

18. An isolated peptide or polypeptide which is 90%, 95% or 99% identical to the peptides or polypeptides of claims 12-17.

19. An isolated peptide or polypeptide of claims 12-17 having an amino acid sequence modified by addition, deletion and/or replacement of one or more amino acid residues and which maintains the biological activity of said peptide or polypeptide.

20. An antibody that specifically binds to a mammalian polypeptide, said polypeptide being defined by the amino acid sequences of claims 12-20.

21. A method for producing an antibody which binds to a peptide or polypeptide of claims 12-19 comprising inoculating an animal with said peptide or polypeptide or with a nucleic acid which encodes said peptide or polypeptide, wherein said animal produces antibodies to said peptide or polypeptide; and  
isolating said antibody.

22. The antibody of claims 21 wherein said antibody is either a polyclonal or monoclonal antibody.

23. Antibody fragments, single chain antibodies or humanized antibodies of the antibodies of claims 20 and 21.

24. An anti-idiotypic antibody of an antibody of claims 21-23.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/08212

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/19 C07K14/52 C12N15/62 C07K19/00 C07K16/24  
C07K16/42 C12Q1/66 C12Q1/68 G01N33/52 G01N33/60

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL EMBEST10, Entry HS558371, Accession number W74558, 21 June 1996 96% identity with Seq.ID:1 nt.16-408 XP002073847	1-9
A	see the whole document	11-19
X	Database EMBL EMBEST11, Entry HSA33733, Accession number AA033733, 26 August 1996 96% identity with Seq.ID:1 nt.48-501 XP002073848	1-9
A	see the whole document	11-19
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 August 1998

Date of mailing of the international search report

18/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Macchia, G

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/08212

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL EMBL10, Entry HS664361, Accession number W74664, 21 June 1996 98% identity with Seq.ID:1 nt.247-702 reverse orientation XP002073865	1-9
A	see the whole document ---	11-19
X	Database EMBL EMBL16, Entry MMW165, Accession number W91165, 9 July 1996 99% identity with Seq.ID:11 nt.1-389 XP002073849	1-9
A	see the whole document ---	11-19
X	Database EMBL EMBL16, Entry MMA44549, Accession number AA044549, 6 September 1996 99% identity with Seq.ID:11 nt.1-498 XP002073850	1-9
A	see the whole document ---	11-19
A	ZHENG M.H. ET AL.: "WHAT'S NEW IN THE ROLE OF CYTOKINES ON OSTEOBLAST PROLIFERATION AND DIFFERENTIATION?" PATHOLOGY RESEARCH AND PRACTICE, vol. 188, no. 8, December 1992, pages 1104-1121, XP000676745 -----	



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/08212

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 21  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.